Maximising the Potential of Radiopharmaceuticals through Novel Targets, Expanded Isotopes & Supply, & Enhanced Dosimetry to Drive Efficacious Therapies From Bench to Approval
Radiopharmaceuticals are no longer an emerging promise - they’re becoming a defining force in next generation medicine. Investment is accelerating, clinical momentum is building, and the field is expanding beyond traditional niches into mainstream oncology.
Breakthrough clinical data, diversified isotope platforms, billion dollar strategic acquisitions, and innovative combination strategies are fuelling unprecedented growth across the sector. Recent highlights from ESMO further underscore this trajectory, revealing compelling Phase 3 readouts, next generation peptide radionuclide therapies, and novel approaches designed to overcome resistance and deliver more durable patient outcomes.
Considering RLTs are around a decade behind where ADCs are today, the real work is occurring behind the scenes. Increased focus on infrastructure, scaling of processes and clinical trial progression are all required to create a well-established ecosystem for the widespread success of RLT.
With major biopharma investing across the value chain, theranostics are now driving precision medicine forward, unlocking new ways to target, treat, and transform cancer care.
That’s why the 5th Annual Targeted Radiopharmaceuticals Summit US returns this year as the TRP Event Series’ largest end-to-end forum dedicated to advancing radioligand therapies from discovery through to market. Taking place July 21–23, 2026, in San Diego, CA, the Summit brings together 260+ leaders across the radiopharmaceutical space including C-level biopharma innovators, nuclear medicine specialists, radiochemists, CDMOs, isotope suppliers, regulators, and investors.
What’s new in 2026?
- A new fourth track adding deeper technical insight, case study driven learning, and actionable solutions to key industry challenges.
- A redesigned agenda structured across Discovery, Preclinical, Clinical, and CMC & Supply Chain.
- Expanded opportunities to connect with the leaders shaping the future of radioligand therapies.
Whether you are exploring alpha emitters, optimizing late-stage trials, engineering next-generation ligands, or seeking strategic partnerships, the 5th TRP Summit US is your gateway to cutting-edge science, actionable insights, and high-value networking - accelerating precision-driven, transformative cancer care.
Join the largest gathering of the TRP event series and be part of the conversations driving the future of radioligand therapies, from discovery and preclinical development to clinical translation and commercial strategy.
Great opportunity to connect, network and catch-up on the latest views on targeted radiopharmaceuticals.
Grant Blouse, Chief Scientific Officer, Therapaint
I enjoyed the opportunity to interact with senior representatives of leading companies in the TRP space and the emphasis on networking and offline discussions.
Kent Iverson, Chief Technology Officer, Photinia Biosciences
Explore the Full Event Guide
- 260+ Attendees from World-Leading RLT Companies
- 58+ Speakers including Novartis, AstraZeneca, RayzeBio & Convergent Therapeutics
- 8+ Hours of Dedicated Networking alongside pioneers in the RLT industry
- 4 Tracks of curated content dedicated to your area of interest
- 22+ C-Suite Speakers with direct influence on their companies’ pipelines & decision-making
Official Partners
Attending Companies Include
Explore Related Events
Explore the Agenda
Discover how leading scientists and clinicians in TRP and radioligand therapy are redefining every stage of development - from target discovery and validation to isotope selection and commercialization strategy. Gain insight into the approaches shaping the next generation of radiopharmaceutical therapies and accelerating their path to the clinic.
Partner With Us
Engage directly with key decision-makers across imaging, radiochemistry, isotope development and more, who are actively seeking collaborations. Explore opportunities to accelerate the development of safer, more effective radiopharmaceuticals and contribute to projects that move quickly from concept to clinical application.
Join TRP Experts
Network with over 260 radiochemists, biologists, clinicians, and R&D leaders who are shaping the full RLT pipeline. Share expertise, exchange ideas, and collaborate across discovery, preclinical development, and clinical translation to advance therapies that can make a real impact for patients.